Apogee Therapeutics Stock (NASDAQ:APGE)
Previous Close
$47.02
52W Range
$25.85 - $72.29
50D Avg
$50.96
200D Avg
$50.67
Market Cap
$2.79B
Avg Vol (3M)
$458.21K
Beta
2.32
Div Yield
-
APGE Company Profile
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.